On 12 Nov 2026 Regeneron Pharmaceuticals closed at $951.19, +23.7% this year; market cap $100.45bn, P/E 20.9.
Health Care · Biotechnology · NASDAQ · United States
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
| Market cap | $100.45bn |
| P/E (trailing) | 20.9 |
| EPS (TTM) | $45.62 |
| Beta | 0.10 |
| Dividend | $3.76 |
| Dividend yield | 0.40% |
| Ex-dividend date | 20 Nov 2026 |
| Latest report | 30 Oct 2026 |
| Next earnings | 30 Jan 2027 |
| YTD | +23.7% |
| 1Y | +40.2% |
| 3Y | +6.4% |
| 5Y | +8.8% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $14.34bn | $4.50bn | $4.08bn |
| 2024 | $14.20bn | $4.41bn | $3.66bn |
| 2023 | $13.12bn | $3.95bn | $3.67bn |
| 2022 | $12.17bn | $4.34bn | $4.42bn |
| 2021 | $16.07bn | $8.08bn | $6.53bn |
We publish no single base value for Regeneron Pharmaceuticals. Our valuation methods put it between $1,428.31 and $2,534.95 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.